CN117120029A - 包含阿卡他定的鼻用组合物 - Google Patents

包含阿卡他定的鼻用组合物 Download PDF

Info

Publication number
CN117120029A
CN117120029A CN202180096503.1A CN202180096503A CN117120029A CN 117120029 A CN117120029 A CN 117120029A CN 202180096503 A CN202180096503 A CN 202180096503A CN 117120029 A CN117120029 A CN 117120029A
Authority
CN
China
Prior art keywords
composition
nasal
alcaftadine
pharmaceutical composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180096503.1A
Other languages
English (en)
Chinese (zh)
Inventor
阿希莱什·夏尔马
巴巴萨海布·阿瓦雷
威拉·沙阿
阿莫尔·艾瓦勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arkham Laboratories Ltd
Original Assignee
Arkham Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arkham Laboratories Ltd filed Critical Arkham Laboratories Ltd
Publication of CN117120029A publication Critical patent/CN117120029A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180096503.1A 2021-04-01 2021-06-14 包含阿卡他定的鼻用组合物 Pending CN117120029A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202121015680 2021-04-01
IN202121015680 2021-04-01
PCT/IB2021/055221 WO2022208146A1 (en) 2021-04-01 2021-06-14 Nasal compositions comprising alcaftadine

Publications (1)

Publication Number Publication Date
CN117120029A true CN117120029A (zh) 2023-11-24

Family

ID=76523258

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180096503.1A Pending CN117120029A (zh) 2021-04-01 2021-06-14 包含阿卡他定的鼻用组合物

Country Status (12)

Country Link
US (6) US20240173331A1 (https=)
EP (1) EP4312973A1 (https=)
JP (1) JP2024512121A (https=)
KR (1) KR20230163413A (https=)
CN (1) CN117120029A (https=)
AU (1) AU2021437358A1 (https=)
BR (1) BR112023019795A2 (https=)
CA (1) CA3213156A1 (https=)
CL (1) CL2023002871A1 (https=)
MX (1) MX2023011546A (https=)
WO (1) WO2022208146A1 (https=)
ZA (1) ZA202308388B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240173331A1 (en) * 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
CN114504037B (zh) * 2022-01-14 2024-12-03 云南中茶茶业有限公司 一种茶叶发酵瓶用出瓶机
US11992493B1 (en) * 2022-10-25 2024-05-28 Liangdan Sun Use of compound or pharmaceutical derivative thereof in inhibiting CaMK2G protein activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3877904D1 (de) 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
PL1919450T3 (pl) 2005-09-01 2014-11-28 Meda Ab Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych
BRPI0710085B8 (pt) * 2006-03-31 2021-05-25 Vistakon Pharmaceutical Llc composições oftálmicas e seus kits
CA2840731A1 (en) * 2011-06-29 2013-01-03 Allergan, Inc. Alcaftadine for use in the treatment of urticaria
CN102283849A (zh) 2011-06-29 2011-12-21 北京阜康仁生物制药科技有限公司 一种含有阿卡他定的药物组合物
WO2019022225A1 (ja) 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
WO2021255622A1 (en) * 2020-06-15 2021-12-23 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
US20240173331A1 (en) * 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine

Also Published As

Publication number Publication date
US20250064825A1 (en) 2025-02-27
KR20230163413A (ko) 2023-11-30
MX2023011546A (es) 2023-10-06
US12274702B2 (en) 2025-04-15
US20240173331A1 (en) 2024-05-30
US20250064827A1 (en) 2025-02-27
BR112023019795A2 (pt) 2023-11-07
EP4312973A1 (en) 2024-02-07
US20260007682A1 (en) 2026-01-08
US20250064826A1 (en) 2025-02-27
WO2022208146A1 (en) 2022-10-06
JP2024512121A (ja) 2024-03-18
CA3213156A1 (en) 2022-10-06
US20250064828A1 (en) 2025-02-27
AU2021437358A1 (en) 2023-09-14
ZA202308388B (en) 2025-11-26
CL2023002871A1 (es) 2024-01-26

Similar Documents

Publication Publication Date Title
JP7791119B2 (ja) アルカフタジンとコルチコステロイドの組み合わせ
US12274702B2 (en) Nasal compositions comprising alcaftadine
EP2522365B1 (en) Compositions comprising azelastine and methods of use thereof
JP5683719B2 (ja) ベポタスチン組成物
US6740660B2 (en) Nasal delivery of apomorphine
US20110294897A1 (en) Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion
EP3705114A1 (en) Ophthalmic composition for treating dry eye and symptoms thereof
US20020002175A1 (en) Nasal delivery of apomorphine in combination with glycol derivatives
RS65099B1 (sr) Intranazalna kompozicija koja sadrži betahistin
RU2854644C1 (ru) Композиции для интраназального применения, содержащие алкафтадин
JPH11147825A (ja) 粘膜吸収性の向上方法及び粘膜外用剤
JP7391026B2 (ja) モメタゾン及びオロパタジンの組み合わせを用いた小児対象におけるアレルギー性鼻炎の治療
WO2026060434A1 (en) Novel eyelid delivery of ophthalmic composition containing muscarinic receptor modulators for prevention and treatment of ocular disorders
EA041383B1 (ru) Интраназальная композиция, включающая бетагистин

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination